Healthcare

• Insilico Medicine (3696 HK) has risen since its 1H26 earnings announcement.  The company’s rentosertib drug reversed biological aging markers in its Phase IIa trial.
• Rentosertib holds a singular distinction: it is the first end-to-end AI-discovered and AI-targeted drug to reach Phase III clinical development globally.
• The China CDE permitted a direct jump from Phase IIa to Phase III based on efficacy data, an unusual regulatory concession.

• Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel, small molecule product candidates to modulate the ribosome and promote readthrough of premature stop codons.
• Exaluren received Orphan Drug Designation from the FDA for AS, with Phase 2b topline data anticipated by mid-2027.
• The company reported net losses of $8.3 million for the six months ended June 30, 2026, with an accumulated deficit of $308.8 million.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• GenScript Biotech (1548 HK) is placing 77M shares at the price of HK$30.50 per placing share. Placing shares represent approximately 3.5% of the total number of issued shares.
• The company intends to use the proceeds mainly for expansion of capacity and infrastructure of AI-driven drug discovery platform, including automated high-throughput wet-lab facilities, related equipment, and laboratory upgrades.
• GenScript is witnessing accelerating demand for AIDD. During 1H26, AIDD business doubled and maintained rapid growth for a third consecutive half-year reporting period.

• Dyadic International, Inc. is a global biotechnology company based in Jupiter, Florida, developing and commercializing precision-engineered, animal-free recombinant proteins and enzymes using proprietary microbial expression platforms.
• The company’s common stock has been listed on Nasdaq under the symbol “DYAI” since April 17, 2019, with 40,063,703 shares outstanding as of September 10, 2026.
• The company has a history of net losses and $6.0 million in 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Revvity is moving to deepen its position in human-relevant drug discovery with the planned acquisition of France-based Human Cell Design, a biotechnology company specializing in human cell models for diabetes, obesity, and other metabolic diseases.
• Announced on September 9, 2026, the transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions, while financial terms remain undisclosed.
• The acquisition would add Human Cell Design’s pancreatic beta cell models to Revvity’s Life Sciences portfolio, extending its capabilities in GLP-1 and broader metabolic drug screening while creating potential applications in regenerative medicine and cell-based therapies.

• Fast Gestation Replicability: Sunway Healthcare Group demonstrates sector-leading hospital ramp-up times, with its newest facilities—SMC Damansara and SMC Ipoh—reaching operational breakeven in under 12 to 15 months (achieving pre-tax and EBITDA breakeven respectively in January 2026). This significantly outperforms the private healthcare industry average of 3 to 5 years.
• High Revenue Intensity Dominance: Sunway boasts the highest average revenue per licensed bed in Malaysia at RM 1.3 million, driven by a high-acuity quaternary care model and specialized centers of excellence. This pricing power, alongside the captive nursing pipeline from Sunway University, forms a robust competitive moat against regional peers IHH Healthcare and KPJ Healthcare.
• Post-IPO Capital Structure Strength: Following its March 18, 2026 listing, Sunway’s net gearing improved from 42% to 11%. This fortifies its balance sheet ahead of the September 18, 2026 lock-up expiration, positioning the company to fund its 3,400-bed 2032 expansion pipeline entirely through organic cash flows and green debt, with minimal reliance on dilutive equity.

• In this insight, I provide an early look at the potential additions and deletions to KOSDAQ150 rebalance in December 2026.
• I provide 9 potential deletion candidates including C&C International Corp (352480 KS), Devsisters (194480 KS), and Webzen Inc (069080 KS). 
• QThe 7 potential addition candidates include Mezzion Pharma (140410 KS), Taihan Fiberoptics (010170 KS), and Seers (458870 KS). 

• Sunway Healthcare Holdings (SUNMED MK) raised US$735m in its Malaysia IPO in March 2026. The lockup on controlling shareholders and Pre-IPO investors is set to expire soon on 18 September.
• Sunway Healthcare Holdings, one of the largest private hospital groups in Malaysia, provides services covering the full lifecycle of care.
• In this note, we will talk about the lockup dynamics and possible placement.

• The company is very good at generating consistently positive operating cash flow
• The tightness of the operation is very good based on the cash conversion cycle
• Looking at the balance sheet, the company has very good access to capital to fund growth

• Circular Dilution and AI Pivot: CDT Equity’s highly publicized pivot from a clinical-stage development model to an AI-powered drug-repositioning platform is primarily a capital-preservation tactic rather than a scientifically validated transition. Its 22.7% equity stake in Sarborg Limited was acquired almost entirely through highly dilutive stock and warrants. Crucially, Sarborg’s own audited financials filed in late August 2026 reveal that it is also operating under a going-concern warning with minimal cash, representing an unstable “paper-buying-paper” structure.
• Flawed Patent Defensibility: While CDT claims its solid-form chemistry and cocrystallization technologies can secure up to 20-year patent extensions on deprioritized assets, formulation and crystalline-phase patents are historically fragile. Generics and biosimilar developers frequently bypass these secondary barriers by designing around specific polymorphs, making CDT’s core IP far less defensible—and less attractive for out-licensing—than traditional new chemical entities (NCEs).
• Solvency and Governance Crisis: CDT is in a state of severe financial distress, holding just $0.7 million in cash as of June 30, 2026, against a projected 12-month working capital need of $19.5 million. This liquidity gap is compounded by a persistent $9.6 million accrued litigation liability stemming from the Strand Hanson High Court judgment, continuous auditor turnover, and extensive material weaknesses in internal controls over financial reporting.

• Strong Core Profitability Inflection: GenScript’s Life Science Group (LSG) has crossed a key utilization threshold, with 1H 2026 adjusted operating profit surging 102.8% to US$94.0 million on a 28.8% revenue increase. This operating leverage is heavily driven by high-throughput automation and the doubling of high-margin AI-driven protein orders.
• Capital Raise Driven by Cap Table Restructuring: The newly announced US$300 million primary placement at HK$30.50 per share is strategically timed to offset the US$225.1 million cash outlay used to buy back Hillhouse Capital’s preferred shares in ProBio. This restructuring cleans up ProBio’s cap table ahead of its newly approved HKEX Main Board spin-off.
• Bifurcated Competitive Landscape: GenScript retains an 80%+ win rate against Twist Bioscience and IDT for long-chain, highly complex genes (>10kb) due to proprietary error-correction algorithms, but loses on pure price ($0.003/base) to Twist for standard, low-complexity gene fragments (<1.5kb). Geopolitical overhang from the BIOSECURE Act is driving US biopharma clients to multi-source, capping GenScript’s near-term US market share expansion.

• Ibezapolstat’s clinical value proposition hinges on a “single-agent” paradigm shift: By achieving a 96% clinical cure rate while actively preserving and enriching key gut phyla (Actinobacteria and Firmicutes), the drug aims to eliminate the need for secondary, costly microbiome-restoring therapies like Vowst or Rebyota.
• Acurx’s capital structure is critically inadequate for a Phase 3 trial: With only $10.66 million in cash as of June 30, 2026, and an ongoing net loss of $2.25 million per quarter, the company’s dependency on highly dilutive capital tools like the $12 million Lincoln Park facility and recent $7.1 million ATM registrations will continue to depress equity value.
• The regulatory path has a theoretical single-trial shortcut, but execution is partner-dependent: Although the FDA’s July 13, 2026 Type C meeting left the door open for a single-trial NDA based on the 550-patient IBZ-ASPIRE protocol, the lack of a formal Special Protocol Assessment (SPA) and Acurx’s weak balance sheet mean clinical initiation will likely stall without an international out-licensing deal.

• Earnings quality is very high based on our analysis of net income relative to operating cash flow
• The efficiency is average when looking at the growth in sales relative to the growth in assets
• The company has delivered moderate sales growth, which is essential for long-term value creation

• GenScript Biotech (1548 HK) is looking to raise up to US$300m from a primary placement. Proceeds are to be used for capacity expansion and platform infrastructure purposes.
• Genscript Biotech is a global life-science platform spanning research tools and services, biologics CDMO (ProBio) and industrial synthetic biology, with additional exposure to cell therapy through Legend Biotech.
• In this note, we will talk about the placement and run the deal through our ECM framework.

• CDT Equity Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.
• The company successfully extended the patent life of certain drugs by up to 20 years.
• The company reported a net loss of $(8,704) for the six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Kyowa Kirin Co Ltd (4151 JP) posted 14% revenue growth in 1H26. Core operating margin expands expanded on lower SG&A and R&D expense.
• Kyowa Kirin reiterated 2026 guidance. They expect revenue to be ¥520B and core operating profit to be ¥130B. Company expects to end the year with a core profit of ¥103B.
• Kyowa Kirin needs new drugs to augment growth. It remains highly dependent on Crysvita. Ziftomenib, infigratinib will drive revenue numbers in medium to long term.

• Bio-Techne Corporation is a premier pure-play life sciences tools and diagnostics provider, holding commanding market share in premium bioactive recombinant proteins, validated research antibodies, automated capillary electrophoresis, and spatial biology assays.
• Despite cyclical post-pandemic biopharma destocking and early-stage biotech funding headwinds, the company demonstrates exceptional structural resilience with consistent gross margins of 64% to 67% and robust cash generation, producing $1.39B to $1.47B in annual free cash flow over recent fiscal years.
• Long-term compounding value is underpinned by a high-margin recurring consumable revenue model, expanding cell and gene therapy bioprocessing exposure (ScaleReady/Wilson Wolf), and leadership in multi-omics spatial biology (ACD RNAscope and Lunaphore).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Gurugram remains the earnings engine, with occupancy improving to 65.7% and Tower IV offering 200+ additional beds for future growth. 
• Raipur has commenced operations, while South Delhi adds a 650+ bed asset-light opportunity, significantly expanding Artemis Medicare’s growth runway. 
• Q1 FY27 revenue grew 12.7% YoY, while PAT rose 48.3%, supported by stronger Gurugram margins, higher ARPOB and operating leverage

• First-in-Class vs. Best-in-Class Divergence: While Genfleet’s KRAS G12C inhibitor fulzerasib (Dupert®) secured first-to-market status in China in August 2024, its long-term commercial upside is capped by intense fast-follower competition from Jacobio/Allist’s glecirasib. However, Dupert® holds a clinical edge with a median PFS of 9.7 months compared to glecirasib’s 8.2 months, backed by the superior commercial commercialization muscle of Innovent Biologics.
• GFH375 (VS-7375) is the Real Value Driver: Genfleet’s oral KRAS G12D (ON/OFF) inhibitor represents a massive clinical leap. Backed by outstanding ESMO 2025 monotherapy data (41% ORR in heavily pretreated pancreatic cancer) and its out-licensing partnership with Verastem Oncology, the asset is entering registrational Phase III trials in China and registrational-directed Phase II TARGET-D trials globally, positioning it far ahead of domestic competitors.
• Strong Capital Runway Supported by Strategic Out-Licensing: Following its September 2025 IPO on the HKEX (2595.HK) and a major HK$ 471.78 million follow-on placement in July 2026, Genfleet’s cash pile stands at a robust RMB 1.78 billion. With a narrowed 1H26 net loss of RMB 220 million, the company has a secure 3-to-4-year financial runway, mitigating the cash-burn anxieties typical of commercial-stage Chinese biotechs.

• Baird Medical (NASDAQ: BDMD) is an established medical device company whose mission is to enhance patient outcomes through minimally invasive precision technology and advanced diagnostic solutions.
• The company is a global leader in microwave ablation treatment for thyroid tumors.
• The company eventually plans to expand this treatment to cover breast nodules, liver cancer and uterine fibroids.

• Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat Gram-positive bacterial infections.
• Acurx Pharmaceuticals, a late-stage biopharmaceutical company, received $9.2 million from sales under a Purchase Agreement and may receive up to $2.8 million additional gross proceeds.
• The auditor’s report includes an explanatory paragraph on the ability to continue as a going concern, and substantial additional capital is needed.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Key points (machine generated)

• Daiko Pharmaceutical aims for sales of 7,200 million yen in FY 2026, a 12.5% increase.
• Operating profit is projected at 500 million yen (up 8.9%), while net profit is expected to decline by 40.4% to 550 million yen.
• The pharmaceutical sector is forecasted to grow with sales of 6,695 million yen, supported by brand investments and rising operating profit.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• Bio-Techne Corporation reported mixed third-quarter fiscal 2026 results amid uneven end-market conditions.
• Total revenue declined 2% organically and on a reported basis to $311.4 million, affected by timing of large OEM commercial supply orders and purchases from two major cell therapy customers that received FDA Fast Track Designations.
• Excluding these timing effects, underlying organic growth was approximately 2%.

• Dongxing Securities (601198 CH) and Cinda Securities (601059 CH) shares will stop trading after 14 September following the merger with China International Capital (601995 CH). 
• There will be buying in China International Capital (601995 CH) from global index trackers at the close on Monday.
• There will be additions and other flows for the CSI 300 Index, CSI 500 Index and the CSI 1000 Index at the time of delisting of Dongxing Securities and Cinda Securities.

• Our 2020 thesis correctly identified Perfect Medical’s cash generation and management discipline, but underestimated how narrow and execution-dependent its moat was.
• The full financial history shows resilience rather than compounding: overseas expansion disappointed, margins compressed sharply, and competitive pressure remained persistent.
• At roughly 9x FY03/2026 earnings with an 11% trailing dividend yield, the stock is interesting again – but the thesis is now stabilization and cash return.

• VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share.
• Sirnaomics develops siRNA medicines, drugs that silence a disease-causing gene before it is turned into protein. The hard part is delivery, and beyond the liver very few groups can do it. The company owns two platforms: PNP, which it places among the world’s few extra-hepatic siRNA delivery systems with clinically proven safety, and GalAhead, which it describes as the only programmable RNAi platform for dosing intervals in global clinical development. Four programmes are in human trials, a fifth is IND-ready, and the company holds global rights across them.
• The five years since listing were costly. Accumulated losses reached US$536.8m, spending was cut from US$91.8m in 2022 to US$15.3m in 2025, and headcount fell from 225 to 37. The audit opinion is qualified and going concern is flagged.

• Genfleet Therapeutics (2595 HK) (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its pre-IPO investors is set to expire soon.
• GFT is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology.
• In this note, we will talk about the lockup dynamics and possible placement.

• Insilico Medicine (3696 HK)‘s lead asset rentosertib has demonstrated potential for biological age reversal. Data from Phase 2a trial shows 3–4 years reversal in biological age.  
• Recently, the company has announced 1H26 result, with revenue increasing 287% YoY to $106M, and achieved its first profitable half-year since listing, with an adjusted net profit of $36M.
• Execution of additional strategic collaborations to maximize the application and commercial opportunity of Pharma.AI platform will be the near-term catalyst.

• Looking at the balance sheet, the company has very good access to capital to fund growth
• The company is very good at generating consistently positive operating cash flow
• The efficiency is very good when looking at the growth in sales relative to the growth in assets

• Ionis Pharmaceuticals has added another major regulatory win to its growing list of RNA-based medicines, with the FDA approving Zanvastro for adults and children with Alexander disease, a devastating neurological disorder that previously had no disease-modifying treatment.
• The approval is medically significant, but the muted stock reaction highlights an important divide between scientific achievement and commercial impact.
• Alexander disease affects an exceptionally small population, limiting Zanvastro’s likely revenue contribution even if adoption is strong.

• Disruptive Proprietary Platform for High-Value Oral Peptide Delivery: Lexaria Bioscience Corp. (LEXX) utilizes its patented DehydraTECH platform—now advanced to DehydraTECH 3.0—to significantly enhance the oral bioavailability, onset speed, and gastrointestinal tolerability of fat-soluble active pharmaceutical ingredients (APIs) and peptides, addressing a multi-billion-dollar commercial opportunity in oral GLP-1/GIP metabolic therapeutics.
• Substantial Preclinical and Clinical Validation: Preclinical and pilot clinical data demonstrate robust performance advantages, including up to a 5-fold increase in oral absorption for next-generation metabolic candidates such as amycretin and retatrutide, validating DehydraTECH as an out-licensing candidate for global pharmaceutical partners seeking needle-free delivery alternatives.
• Fortified Non-Dilutive Capital and Asset-Light Licensing Model: Supported by an Australian Tax Office R&D cash rebate of AUD$3.67 million (~USD$2.6 million), recent warrant exercises, and a zero-debt balance sheet, Lexaria maintains an extended operational runway to execute its 2026/2027 clinical roadmaps and secure high-margin pharmaceutical licensing agreements.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Alcon’s second quarter 2026 results reflected modest growth supported by a broad-based contribution across its Surgical and Vision Care franchises.
• Sales increased 7% year-over-year to $2.8 billion, with surgical sales rising 7% and Vision Care sales also up 7%.
• Equipment sales, particularly from the UNITY platform, grew 25%, underscoring the commercial success of recent innovations.

• On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in adults with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) Congress 2026.
• Both studies met their primary endpoint with median triglyceride reductions from baseline of 79% and 81%, respectively.
• In addition, more than 90% of treated patients achieved triglyceride levels <500 mg/dL, which is below the threshold for sHTG.

• Cardinal Health, Inc. concluded fiscal year 2026 with marked financial improvements driven primarily by its Pharmaceutical and Specialty Solutions segment, which benefited from resilient demand and specialty business strength.
• The company reported a 6% increase in total revenue for the fourth quarter to $63.7 billion and a 14% rise for the full year to $254 billion, with operating earnings growing 30% year-over-year and earnings per share increasing by 40% in the quarter.
• Adjusted free cash flow reached $5 billion, reflecting strong operational execution and favorable demand across its portfolio.

• Hims & Hers Health reported second-quarter 2026 results marked by strong growth and continued investment in technology, broader offerings, and international expansion.
• Revenue increased nearly 40% year-over-year to more than $753 million, supported by 300,000 net new subscribers, bringing the total to nearly 3 million.
• U.S. revenue reached $622 million, with domestic growth accelerating to 16% on an expanded weight loss portfolio.

• Zacks Small-Cap Research Note for Lexaria Bioscience Corp. (LEXX)

• AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained AbbVie has moved quickly to deepen its immunology franchise, completing its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026, after first announcing the transaction during the second quarter.
• The purchase is AbbVie’s largest bolt-on deal since 2019 and adds a portfolio of long-acting biologics targeting atopic dermatitis, respiratory conditions, and other immune-mediated diseases.
• Management has framed Apogee as a strategic addition to a pipeline already anchored by Skyrizi and Rinvoq, with the aim of extending growth into the 2030s and beyond.

• The company has delivered strong sales growth, which is essential for long-term value creation
• The company is very good at generating consistently positive operating cash flow
• The efficiency is very good when looking at the growth in sales relative to the growth in assets

• Marksans Pharma posted its highest-ever quarterly EBITDA (INR 213 crore) and PAT (INR 159 crore) in Q1FY27, with UK and Europe overtaking as a genuine second growth engine.
• Operating leverage, a bolt-on European buildout and a cash pile crossing INR 1,000 crore reshape the growth and capital allocation narrative heading into FY27.
• Management’s conservative guidance hold, flagged margin normalization and looming capacity constraints deserve closer scrutiny than the headline beat suggests.

• Defensive options positioning dominated the week of August 31.
• Across five high-severity pulses, traders piled into protective puts on names nursing sharp price declines.
• The put/call ratio (PCR) – which measures put volume relative to call volume – spiked well above seasonal norms on multiple names, with several readings hitting 52-week extremes.

• The second quarter of 2026 for Dentsply Sirona reflected a continued transitional phase as the company progresses through its 24-month Return-to-Growth Action Plan.
• Reported revenues declined by 4.1% to $898 million, or 6.3% on a constant currency basis, though after adjusting for the divestiture of Byte and planned dealer inventory reductions, the decline was somewhat mitigated to 3.6%.
• Earnings per share remained stable at $0.52, benefiting from $44 million in tariff refunds which contributed approximately $0.17 per share.

• Over five sessions, directors and substantial shareholders filed 25 acquisitions and 16 disposals for over 40 primary-listed stocks.
• Executive Chairman Ow Chio Kiat increased stakes in Stamford Land and Singapore Shipping Corporation, holding over 40% interests in both.
• Keppel DC REIT completed an upsized S$625 million placement to fund a Japan hyperscale data centre acquisition.

Key points (machine generated)

• internet infinity INC. achieved record-high operating profits in FY3/26, with a 14.2% increase in net sales to ¥5,892 million and a 33.8% rise in operating profit to ¥536 million.
• For FY3/27, the company projects a 3.5% increase in net sales to ¥6,100 million and a 25.0% rise in operating profit to ¥670 million, driven by growth in its DX Solution Business.
• The company aims for net sales of ¥8,143 million and operating profit of ¥1,343 million by FY3/30, focusing on balancing growth in existing businesses with digital transformation investments.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Key points (machine generated)

• internet infinity INC. achieved record-high operating profits following its acquisition of SAINT-WORKS.
• The company provides various healthcare services for older adults, including rehabilitation care and welfare equipment leasing.
• For the fiscal year ending March 2026, internet infinity reported a 14.2% increase in net sales, totaling ¥5,892 million.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• The company has delivered strong sales growth, which is essential for long-term value creation
• The efficiency is very good when looking at the growth in sales relative to the growth in assets
• The company is very good at generating consistently positive operating cash flow

• BridgeBio Pharma reported continued commercial progress in the second quarter of 2026, led by strong growth of Attruby, or acoramidis, for transthyretin amyloid cardiomyopathy.
• Net product revenue reached $222.4 million, increasing sequentially by more than $35 million.
• Attruby grew 23%, exceeding overall market growth of 19%.

• RadNet, Inc. reported its second quarter 2026 financial results marked by strong growth and record performance across both its Imaging Center and Digital Health segments.
• The company’s total revenue increased by 25% year-over-year to $622.7 million, while adjusted EBITDA rose by 22.7% to $99.7 million.
• This broad-based growth was supported by higher procedural volumes, including a notable shift toward advanced imaging modalities such as MRI, CT, and PET/CT, which contributed to an increase in the advanced imaging mix from 27.5% to 29.9% of total procedural volume.

• Shionogi & Co (4507 JP) announced Q1FY27 result, with revenue and all profit categories achieving record-high for the first quarter, driven by existing businesses and integration effects from acquired businesses.
• Progress rate of key parameters of Q1FY27 against H1FY27 guidance is strong, thereby enhancing our conviction on the company meeting guidance.
• Addition of growth drivers in multiple QOL diseases that are not affected by fluctuations in infectious disease outbreaks, together with contributions from acquired products should lead to accelerated profitable growth.

• Toscafund’s 250p proposal is now a recommended, fully financed Scheme, backed by Three Hills and Ares, with irrevocables covering 42.7% of Scheme Shares.
• Even at 100% turnout, Bidco needs support from only 56.4% of remaining uncommitted Scheme Shares. We assign 90% completion probability.
• More than 60 potential buyers were contacted over eight months. No higher executable proposal emerged, leaving limited scope for a topping bid.

• The S086 (Xinchaotuo) Commercial Execution is the Real Growth Driver: Following its May 2025 NMPA approval for primary hypertension and its subsequent December 2025 inclusion in the National Reimbursement Drug List (NRDL), S086 has become Salubris’s primary growth engine. Along with Enarodustat (Enaro), innovative formulation revenues grew 26.84% year-on-year in the first half of 2026, offsetting the commoditized legacy generic portfolio.
• The JK07 Phase II Clinical Disappointment Redraws the Valuation Curve: In May 2026, the interim data release for the RENEU-HF Phase II trial of JK07 (an NRG-1 fusion protein) revealed that the primary endpoint of Left Ventricular Ejection Fraction (LVEF) improvement at 26 weeks did not achieve statistical significance over placebo. While Salubris highlighted positive subjective KCCQ score improvements, the lack of robust structural efficacy significantly increases the regulatory risk and delays both the domestic and U.S. clinical pathways.
• HKEX Listing Resubmission Points to Urgent Liquidity Needs: On September 3, 2026, Salubris resubmitted its listing application to the Main Board of the HKEX, sponsored by Goldman Sachs, Citigroup, and CITIC Securities, after its initial February 2026 filing lapsed in August. The push for Hong Kong capital is driven by a desire to fund expensive global clinical trials and provide a dedicated offshore capital runway, amidst close scrutiny from the CSRC regarding overseas capital allocations.

• Innovent Biologics Inc (1801 HK) 1H26 revenue grew over 45% YoY, as oncology segment witnessed ramp up of newly NRDL-listed products and general biomedicine portfolio expanded.
• The global innovation pipeline is progressing smoothly. Three high-potential assets have entered global Phase 3 clinical trials, with a combined potential addressable market exceeding US$ 60B.
• Ongoing product launches and robust pipeline will support the growth momentum of the company. Innovent aims to achieve RMB 20B product revenue in 2027 (~ RMB 35-40B by 2030).

• Innova Captab is a top-tier Indian Contract Development and Manufacturing Organization (CDMO) with strong vertical integration across Active Pharmaceutical Ingredients (APIs) and finished formulation dosage forms, currently partnering with 14 of India’s top 15 pharmaceutical companies.
• Financial performance reflects robust scaling, with annual revenue expanding from INR 10,773.86M in 2024 to INR 16,051.02M in 2026 (~22% CAGR) and Net Income reaching INR 1,431.83M, supported by a pivotal inflection to positive Free Cash Flow of INR 340.72M in 2026 as major capital expenditures mature.
• Structural tailwinds from mandatory revised Schedule M compliance enforcement are driving industry consolidation toward organized CDMOs; however, Innova’s current valuation of 43.0x P/E and 6.2x P/B reflects an earned premium over pure formulation peers, requiring sustained capacity ramp-up and margin execution at its newly commissioned Jammu facility.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• BIOSECURE Act tailwinds are directionally real but commercially lagged: While WuXi AppTec’s addition to the US Department of Defense’s 1260H list on June 8, 2026, has triggered a 35% to 45% increase in Requests for Proposals (RFPs) across Indian CRDMOs, legacy contracts are protected until 2032. Actual order-book translation is bottlenecked by 12 to 18-month tech transfer cycles and high clinical-stage switching costs.
• Aragen’s early-to-late stage cross-selling is structurally constrained: Despite marketing a “concept-to-clinic” pipeline, Aragen’s historical core is early-stage discovery chemistry (legacy GVK Bio). Transitioning discovery clients into late-stage CDMO manufacturing is limited by a 90%+ molecule attrition rate in Phase I/II and a lack of large-scale commercial API infrastructure compared to tier-1 Indian peers.
• The US Biologics footprint (Morgan Hill) operates at a structurally lower margin: The California-based Aragen Bioscience site is confined to non-GMP early-stage cell-line development. Bridging this to the new Bengaluru (Jigani) GMP facility is operationally difficult, as US biotechs show extreme reluctance to transfer clinical-scale cell lines and process parameters across geographies due to supply chain and oversight friction.

• A leading Chinese pharmaceutical company focused on the CKM sector, engaged in R&D, production, and sales of pharmaceuticals and medical devices. It seeks a primary HKEX listing, having been listed.
• The company ranked second in China’s in-hospital cardiovascular drug sales with 11.3% market share in 2025. Total revenue increased to RMB4,352.7 million in 2025.
• Gross profit was 3,247,584 RMB’000 and profit for the year was 652,784 RMB’000 in 2025. Total assets reached 11,297,803 RMB’000 as of December 31, 2025.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Sacra estimates that Scan.com reached $165M in annualized revenue in August 2026, up from $105M at the end of 2025.
• Scan.com has raised approximately $279M in lifetime financing, comprising roughly $149M in equity and $130M in debt facilities.
• Scan.com connects patients, payers, and clinicians with independent imaging centers through a single digital layer.

• The September 2026 index review results for the T50, T100, and TDIV indices were confirmed after market close on Friday 4th September 2026.
• There will be 1 ADD/DEL for T50 and 3 separate ADDs/DELs for T100.
• We correctly predicted all of these changes except for one.

• Aragen Life Sciences Limited (ALS IN) is looking to raise at least US$300m in its upcoming India IPO. The deal will be run by Axis, Citi, GS, JM Financial.
• Aragen Life Sciences Limited (ALS) is an India-based, fully integrated contract research, development, and manufacturing organization (CRDMO).
• ALS offers a platform of solutions across the entire drug lifecycle, which spans from contract discovery and preclinical research to contract development and manufacturing for both small molecules and biologics.

• Cytokinetics reported its second quarter 2026 results amid early-stage commercialization of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and positive clinical developments extending its cardiology pipeline.
• The company highlighted encouraging commercial momentum, with U.S. net product revenues from MYQORZO reaching $23 million and European launch initiation, particularly in Germany, contributing an additional $2.3 million.
• As of quarter-end, over 700 U.S. healthcare providers had prescribed MYQORZO, with more than 1,500 patients having received the drug, marking an approximate tripling from the first quarter.

• Haemonetics Corporation reported first quarter fiscal year 2027 results demonstrating continued profitable growth, with revenues totaling $339 million, reflecting a 6% increase both on a reported and organic basis.
• Adjusted earnings per diluted share rose 4% to $1.14.
• The company operates through three core platforms—Plasma, Blood Management Technologies (BMT), and Interventional Technologies (IVT)—all of which contributed positively to the quarter’s performance.

• Halozyme Therapeutics reported strong second quarter 2026 financial and operating results, driven by significant growth in royalty revenues from its ENHANZE technology platform.
• Total revenues rose 48% year-over-year to $481 million, while royalty revenues increased 50% to $308 million.
• Results exceeded company expectations, supported by six ENHANZE-enabled products.

• 10x Genomics reported second quarter 2026 revenue of $151 million, including $1.6 million from license and royalty settlements.
• Excluding these nonrecurring items, revenue grew 3% year-over-year to $149 million.
• The company’s consumables revenue rose 7%, driven by 3% growth in Single Cell and 16% growth in Spatial consumables.

• Viatris reported second-quarter 2026 financial results reflecting continued operational revenue growth, strong profitability, and progress across its global product portfolio and pipeline.
• Total revenues were $3.8 billion, representing a 3.5% operational increase year-over-year, driven primarily by growth in Greater China and solid performance in complex generics and branded products in North America.
• Adjusted EBITDA was $1.2 billion, and adjusted EPS reached $0.69, both exceeding company expectations.

• Ascentage Pharma (6855 HK) reported revenue of RMB 302.2M in 1Q26 (up 29% YoY), from the sales of pharmaceutical products, commercialization rights income from Innovent Suzhou and service income.
• R&D cost will continue to tread on a higher trajectory. Company will continue to advance enrolment in the trials and actively advance inclusion of Lisaftoclax in China’s NRDL in 2026.
• Building on the differentiated clinical profile of both products, Ascentage is well positioned to accelerate market penetration and prepare for potential new indication approvals and upcoming NRDL inclusion opportunities.